secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2026-09-22T11:06:19+00:00
Accession:  0001193125-26-397219
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking VK2735: 33-week weight loss 22% via weekly dosing; QOW/QM maintenance holds up to 97%/90%
--------------------------------------------------------------------------------

- VK2735 maintenance study (N≈180, BMI≥30): weekly 17.5 mg led to 21.7% mean weight loss from baseline at 33 weeks; placebo gain 0.3%, p<0.0001; no plateau.
- Induction (21 wks weekly): 16-19% weight loss across 15-22.5 mg vs ~0% placebo, p<0.0001; 98% achieved ≥5%, 32% ≥20% loss.
- After transitioning to every-other-week dosing for 12 weeks, maintained up to 97% of Week 21 weight loss vs 61% placebo, p<0.0001.
- Monthly dosing for 12 weeks maintained up to 90% of Week 21 weight loss vs 61% placebo (p=0.0002); separation from placebo by week 4.
- GI AE rates similar to placebo during maintenance; 1% discontinued due to AE in induction; oral maintenance part 2 planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/0001193125-26-397219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-20260922.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-397219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer